Weekly Docetaxel and Bortezomib in the Treatment of Advanced Hormone-Refractory Prostate Cancer
Evaluation of the effectiveness of weekly docetaxel/bortezomib as first-line chemotherapy for patients with advanced hormone-refractory prostate cancer.
Prostate Cancer
DRUG: Docetaxel|DRUG: Bortezomib
objective response rate
progression-free survival|overall survival
Upon determination of eligibility, patients will be receive:

* Docetaxel + Bortezomib

Patients with objective responses or stable disease will continue treatment for eight courses or until disease progression is documented.